【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 27
3.2 Staging Systems 30
3.3 Response and Relapse Criteria 31
3.4 Symptoms 33
3.5 Prognosis 34
3.6 Quality of Life 35
4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and Comorbidities 39
4.3 Global Trends 40
4.3.1 Incidence 40
4.3.2 Survival Rates for Multiple Myeloma – 8MM 43
4.4 Forecast Methodology 44
4.4.1 Sources Used 46
4.4.2 Sources Not Used 48
4.4.3 Forecast Assumptions and Methods, Multiple Myeloma Diagnosed Incident Cases 48
4.4.4 Forecast Assumptions and Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases 49
4.4.5 Forecast Assumptions and Methods, Multiple Myeloma Clinical Stages at Diagnosis 50
4.5 Epidemiological Forecast for Multiple Myeloma (2013-2023) 50
4.5.1 Diagnosed Incident Cases of Multiple Myeloma 50
4.5.2 Age-Specific Diagnosed Incident Cases of Multiple Myeloma 52
4.5.3 Sex-Specific Diagnosed Incident Cases of Multiple Myeloma 54
4.5.4 Age-Standardized Diagnosed Incidence of Multiple Myeloma 56
4.5.5 Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis 57
4.5.6 Five-Year Diagnosed Prevalent Cases of Multiple Myeloma 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 60
4.6.3 Strengths of the Analysis 61
5 Disease Management 62
5.1 Treatment Overview 62
5.2 Diagnosis 63
5.3 Clinical Practice 64
5.3.1 Primary Therapy for SCT-Eligible Patients 65
5.3.2 Primary Therapy for Non-SCT Patients 67
5.3.3 Salvage/Relapse Therapy 68
5.3.4 Leading Prescribed Drugs 69
5.4 US 71
5.4.1 Diagnosis 72
5.4.2 Clinical Practice 73
5.5 France 75
5.5.1 Diagnosis 76
5.5.2 Clinical Practice 77
5.6 Germany 77
5.6.1 Diagnosis 79
5.6.2 Clinical Practice 79
5.7 Italy 79
5.7.1 Diagnosis 81
5.7.2 Clinical Practice 81
5.8 Spain 83
5.8.1 Diagnosis 84
5.8.2 Clinical Practice 84
5.9 UK 85
5.9.1 Diagnosis 86
5.9.2 Clinical Practice 87
5.10 Japan 87
5.10.1 Diagnosis 88
5.10.2 Clinical Practice 89
5.11 China (Urban) 90
5.11.1 Diagnosis 91
5.11.2 Clinical Practice 92
6 Competitive Assessment 93
6.1 Overview 93
6.2 Product Profiles – Proteasome Inhibitors 93
6.2.1 Velcade (Bortezomib) 93
6.2.2 Kyprolis (Carfilzomib) 100
6.3 Product Profiles – Immunomodulators 108
6.3.1 Revlimid (Lenalidomide) 108
6.3.2 Pomalyst/Imnovid (Pomalidomide) 115
6.4 Other Therapeutic Classes 120
7 Unmet Need and Opportunity 121
7.1 Overview 121
7.2 Treatment of High-Risk Patients 121
7.2.1 Unmet Need 121
7.2.2 Gap Analysis 122
7.2.3 Opportunity 123
7.3 Treatment of Patients with Smoldering Myeloma 123
7.3.1 Unmet Need 123
7.3.2 Gap Analysis 125
7.3.3 Opportunity 125
7.4 Treatment of Extramedullary Disease 126
7.4.1 Unmet Need 126
7.4.2 Gap Analysis 126
7.4.3 Opportunity 127
8 Pipeline Assessment 128
8.1 Overview 128
8.2 Promising Drugs in Clinical Development 128
8.2.1 Farydak (Panobinostat) 128
8.2.2 Ixazomib 135
8.2.3 Empliciti (Elotuzumab) 140
8.2.4 Daratumumab 146
8.2.5 Aplidin (Plitidepsin) 151
8.3 Promising Drugs in Early-Stage Development 155
8.3.1 Oprozomib (ONX-0912) 155
8.3.2 Filanesib 156
8.3.3 SAR650984 156
8.3.4 Marizomib 158
8.3.5 Evofosfamide 158
8.3.6 LGH447 159
8.3.7 Selinexor (KPT-330) 159
9 Current and Future Players 161
9.1 Overview and Trends in Corporate Strategy 161
9.2 Company Profiles 164
9.2.1 Millennium Pharmaceuticals/Takeda 164
9.2.2 Celgene 166
9.2.3 Onyx Pharmaceuticals/Amgen 168
9.2.4 Novartis 169
9.2.5 AbbVie 171
9.2.6 Bristol-Myers Squibb 172
9.2.7 Janssen 173
10 Market Outlook 175
10.1 Global Markets 175
10.1.1 Forecast 175
10.1.2 Drivers – Global Issues 182
10.1.3 Barriers – Global Issues 183
10.2 US 184
10.2.1 Forecast 184
10.2.2 Key Events 188
10.2.3 Drivers – US 188
10.2.4 Barriers – US 190
10.3 5EU 191
10.3.1 Forecast 191
10.3.2 Key Events 196
10.3.3 Drivers – 5EU 196
10.3.4 Barriers – 5EU 198
10.4 Japan 200
10.4.1 Forecast 200
10.4.2 Key Events 203
10.4.3 Drivers – Japan 203
10.4.4 Barriers – Japan 204
10.5 China (Urban) 205
10.5.1 Forecast 205
10.5.2 Key Events 208
10.5.3 Drivers – China (Urban) 208
10.5.4 Barriers – China (Urban) 209
11 Appendix 211
11.1 Bibliography 211
11.2 Abbreviations 233
11.3 Methodology 237
11.4 Forecasting Methodology 237
11.4.1 Diagnosed Multiple Myeloma Patients 237
11.4.2 Percent of Drug-Treated Patients 238
11.4.3 Drugs Included in Each Therapeutic Class 238
11.4.4 Launch and Patent Expiry Dates 239
11.4.5 General Pricing Assumptions 240
11.4.6 Individual Drug Assumptions 241
11.4.7 Pricing of Pipeline Agents 248
11.4.8 Generic Erosion 255
11.5 Primary Research – KOLs Interviewed for this Report 256
11.6 Primary Research – High-Prescriber Survey 258
11.7 About the Authors 259
11.7.1 Analyst 259
11.7.2 Therapy Director 259
11.7.3 Epidemiologist 259
11.7.4 Global Head of Healthcare 260
11.8 About GlobalData 261
11.9 Disclaimer 261
【レポート販売概要】
■ タイトル:多発性骨髄腫治療薬の世界市場予測および分析(~2023)■ 英文:PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
■ 発行日:2015年11月1日
■ 調査会社:GlobalData
■ 商品コード:GDHC114PIDR
■ 調査対象地域:グローバル
- ロボットトータルステーションの世界市場:0.5 ”-1 ”精度、2 ”-その他の精度The global robotic total station market size is expected to reach $930.6 million in 2026, from $568.6 million in 2018, growing at a CAGR of 6.4% from 2019 to 2026. A robotic total station is an electronic equipment, which has ability of measuring angles, and sloping distance in the construction industry. In other words, it is a precision measurement which is used for measuring angles with a movabl …
- イタリアの分子診断・検査市場2014This report provides an overview of the Italian molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.Table of ContentsBusiness Environment Market Structure Market Size, Growth, and Major Suppliers' Market Shares List of TablesMolec …
- 発電業界のM&A及び投資動向(月別):March 2013Power Monthly Deal Analysis - March 2013: M&A and Investment Trends Summary GlobalData's “Power Monthly Deal Analysis - March 2013: M&A and Investment Trends” report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing …
- 世界の医療用バイオセンサー市場(2014-2018)About Medical biosensors are used to analyze biological components with the help of physicochemical detectors. These biosensors monitor health status, disease betterment, and therapeutic treatment outcomes through invasive and non-invasive methods. They are cost-effective and user-friendly devices. Also, they are standardized to minimize errors during the diagnosis of patients. Medical biosensors …
- 世界における貧血症/ビタミン検査製品のパイプライン動向2015Anemia / Vitamin Tests - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Anemia / Vitamin Tests - Pipeline Review, 2015" provides an overview of Anemia / Vitamin Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major play …
- 世界のウエアラブル技術市場:フィットネス、mヘルス、拡張現実、カメラ、e-テキスタイルWearable technology is the buzzword of 2014. A market that has existed for decades, the supporting technologies and public interest are finally sufficient for it to flourish. In an environment heading towards a connected homes paradigm, the next step in our technological evolution is bringing control closer than arm’s reach. Wearables dominated 2014’s CES, with many major OEMs moving into their se …
- 医療用ガスの世界市場分析:製品タイプ別(医療用空気、二酸化炭素、酸素、窒素、亜酸化窒素、ヘリウム、二酸化炭素 – 酸素混合物、Oxyfume 2000、血液ガス混合物)、機器別(マニホールド、真空システム、警報システム、流量計、シリンダー)、用途別(治療、診断、創薬開発、臨床研究、品質管理)、地域別(アメリカ、カナダ、ドイツ、英国、中国、インド、ブラジル、メキシコ、南アフリカ、中東)、セグメント予測The medical gases market is expected to reach USD 15.1 billion by 2024, according to a new report by Grand View Research, Inc. The medical gases market is anticipated to witness a positive growth during the study period from 2016 to 2024. This growth is attributed to a majority of factors, such as the high prevalence of chronic diseases including heart diseases, stroke, asthma, cancer, diabetes, a …
- Subarachnoid Hemorrhage:グローバル臨床試験レビューH2, 2013Subarachnoid Hemorrhage Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Subarachnoid Hemorrhage Global Clinical Trials Review, H2, 2013" provides data on the Subarachnoid Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Subarachnoid Hemorrhage. It includes an overview of the trial numbers …
- 世界のSyrup&Spread市場動向(2014年4月):ニュース・イベントSynopsis Using this report, marketers will effectively gain an insight into the latest happenings in the global syrups & spreads market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global syrups & spreads market on a monthly basis. Scope The report provides a review of the latest news and key events in …
- PEG化タンパク質の世界市場予測:PEG化キット、PEG化試薬The global PEGylated proteins market is expected to USD 1,137.8 Million by 2021 from USD 690.6 Million in 2016, at a CAGR of 10.5% between 2016 and 2021. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circu …
- レベルセンサーの世界市場:タイプ別(接触、非接触)、用途別(連続レベルモニタリング、ポイントレベルモニタリング)、最終用途別(自動車、航空宇宙および防衛、エネルギーおよび電力、ヘルスケア、産業、その他)The global level sensor market is expected to generate revenue worth $4,446.90 million in 2019, and is projected to reach $7,368.10 million by 2026, to register a CAGR of 6.50% during the forecast period. Level sensor is a device that determines the level of fluids or other substances that flow in an open or closed system. There are two types of level measurements, namely, continuous and point lev …
- 原発性硬化性胆管炎(Primary Sclerosing Cholangitis)の治療薬パイプライン動向(2015年上半期版)Primary Sclerosing Cholangitis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Pipeline Review, H1 2015’, provides an overview of the Primary Sclerosing Cholangitis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis, complete with comparative analysis at various stage …
- 世界のMeat市場動向:ニュース・イベント(2014年5月)Synopsis The report provides a review of the latest news and key events in the global meat market during May 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global meat market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global meat market o …
- 世界の航空用ファスナー市場:用途別、材料別、地域別Global Aerospace Fasteners Market: About this market Technavio’s aerospace fasteners market analysis considers sales from aluminum, titanium, superalloys, and steel materials. Our study also finds the sales of aerospace fasteners in APAC, Europe, MEA, North America, and South America. In 2019, the aluminum segment had a significant market share, and this trend is expected to continue over the fore …
- Alirocumab(ACS/急性冠症候群):医薬品市場予測及び分析(~2023)Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of whic …